LTR Pharma has formalised its US commercialisation strategy by signing a definitive agreement with telehealth leader Shed, targeting at least 150,000 ROXUS units in the first year through digital men’s health platforms.
- Definitive US commercial agreement with Shed executed
- Shed commits to minimum 150,000 ROXUS units first year
- ROXUS to launch via Shed's Mavrox and tryshed.com platforms
- Agreement reduces execution risk ahead of US launch
- Partnership leverages Shed’s telehealth infrastructure and patient acquisition
Definitive Agreement Advances US Commercialisation
LTR Pharma (ASX:LTP) has converted its previously announced binding term sheet with Shed Holdings LLC into a definitive commercial agreement, marking a significant step toward the US launch of ROXUS®, its rapid-onset intranasal erectile dysfunction (ED) treatment. This formal contract establishes the operational, marketing, and branding framework for the partnership, setting the stage for a coordinated commercial rollout through Shed’s telehealth platforms.
Shed will distribute ROXUS primarily via Mavrox™, its dedicated men’s health digital platform, as well as its broader telehealth site, tryshed.com. This approach provides US patients with a streamlined, clinician-led pathway to consultation and treatment, leveraging Shed’s established telehealth infrastructure and patient acquisition capabilities.
Volume Commitment Reflects Confidence in Market Demand
Highlighting its confidence in ROXUS’s market potential, Shed has committed to delivering no fewer than 150,000 units within the first 12 months post-launch. This volume commitment underpins Shed’s exclusivity rights in the US telehealth channel and forms a key part of the performance framework agreed between the parties.
For LTR Pharma, this deal represents a major milestone in its US commercialisation strategy, reducing execution risk by partnering with a seasoned telehealth operator rather than building its own infrastructure from scratch. The collaboration combines LTR’s clinically differentiated intranasal treatment with Shed’s expertise in digital marketing, licensed clinician networks, and patient fulfilment.
Preparing for Commercial Launch and Patient Access
Preparations for the commercial launch are already underway, with ROXUS now featured on the Mavrox platform ahead of launch and a patient waitlist established. Both companies are focused on completing the remaining implementation activities necessary to support a smooth market entry.
LTR Pharma Executive Chairman Lee Rodne emphasised the strategic value of the partnership, noting that Shed’s platform offers a credible and scalable US market entry point. Morley Baker, CEO of Shed and Mavrox, described ROXUS as a genuinely differentiated product in a category lacking recent innovation, positioning it well for US patient uptake.
Strategic US Partnerships Build Commercial Momentum
This agreement with Shed follows LTR Pharma’s recent move to secure Strive Specialties as its exclusive US pharmacy fulfilment partner, a critical piece in the distribution puzzle supporting multi-channel commercialisation, including telehealth and provider networks. Together, these partnerships form the backbone of LTR Pharma’s US market strategy for ROXUS, aiming to capture a meaningful share of the sizeable erectile dysfunction treatment market.
While the definitive agreement reduces uncertainty, the company notes that actual commercial launch timing and sales volumes remain subject to risks and contingencies inherent in market entry and regulatory environments.
Bottom Line?
LTR Pharma’s definitive US deal with Shed sets a credible commercial launch path for ROXUS, but execution risks remain as market entry approaches.
Questions in the middle?
- Will Shed meet or exceed its 150,000-unit delivery commitment in year one?
- How will competition in the US telehealth ED market affect ROXUS uptake?
- What regulatory or operational hurdles remain before commercial launch?